China’s Emerging Global Vaccine Footprint

While demand for COVID-19 vaccines may be decreasing, the pandemic highlighted the long-term importance of boosting local vaccine manufacturing in developing countries. China’s role as a key vaccine donor and provider during the pandemic has positioned it to support this new agenda, making it a critical emerging player in the global vaccine manufacturing landscape. As a mission-driven consultancy looking to encourage China’s engagement in global health, Bridge Consulting aims to identify and drive China’s involvement in this important endeavor.

Article Series: Towards Africa's Local Vaccine Manufacturing

International opportunities for vaccine manufacturers under Africa’s PAVM

Exploring New Landscapes for China’s Continued Vaccine Outreach

Latest News

Pandemic Preparedness

Africa CDC, IVI, and Korea Disease Control and Prevention Agency join forces to forge partnerships for vaccine access and health security in Africa at the 2024 Korea-Africa Summit — IVI

South Korea, India, the United States, Japan, and the European Union (EU) have come together to launch the Biopharmaceutical Alliance, to put joint efforts into building a resilient biopharma supply chain, and coordinate the respective countries’ bio policies, regulations, and research and development support measures, in response to potential drug supply shortages as previously seen during COVID-19 — The Hindu

Joint Vaccine Production

Sinovac plans to invest US$100 million into Brazil’s local production of vaccines and monoclonal antibodies, and research in cell therapies. Over the past few years, Sinovac has worked extensively with Brazil’s Butantan Institute on COVID-19 vaccines, and with Fiocruz on vaccine R&D — Sinovac